Free Trial

Day One Biopharmaceuticals Q2 2024 Earnings Report

Day One Biopharmaceuticals logo
$12.47 -0.17 (-1.34%)
(As of 03:51 PM ET)

Day One Biopharmaceuticals EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.75
Beat/Miss
Beat by +$0.70
One Year Ago EPS
N/A

Day One Biopharmaceuticals Revenue Results

Actual Revenue
$8.19 million
Expected Revenue
$0.90 million
Beat/Miss
Beat by +$7.29 million
YoY Revenue Growth
N/A

Day One Biopharmaceuticals Announcement Details

Quarter
Q2 2024
Time
TAS
Uncover the Top Gold Stock of the Bull Market (Ad)

Gold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?

Click here to see how this opportunity could transform your portfolio.

Day One Biopharmaceuticals Earnings Headlines

Day One price target lowered to $34 from $39 at JonesResearch
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Day One Biopharmaceuticals (DAWN) Gets a Buy from Piper Sandler
See More Day One Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Day One Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Day One Biopharmaceuticals and other key companies, straight to your email.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

View Day One Biopharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings